Category Press Releases

Cagent Vascular Unveils New Serranator SL-PRO Product for CLTI and Pedal Disease

Cagent Vascular Announces the Launch of Serranator SL-PRO™ for Pedal and Tibial Disease Treatment Cagent Vascular a leader in the development of cutting-edge serration technology for vessel dilation in endovascular procedures, has unveiled its latest innovation: the Serranator SL-PRO™ PTA…

Read MoreCagent Vascular Unveils New Serranator SL-PRO Product for CLTI and Pedal Disease
Reports

Algiax Reports Positive Phase 2a Results for AP-325 in Neuropathic Pain

Reports Algiax Pharmaceuticals Announces Positive Phase 2a Results for AP-325 in Neuropathic Pain Reports Algiax Pharmaceuticals, a clinical-stage biotechnology company dedicated to developing innovative therapies for chronic neuropathic pain, has announced compelling topline results from its Reports Phase 2a proof-of-concept…

Read MoreAlgiax Reports Positive Phase 2a Results for AP-325 in Neuropathic Pain
Cosette

Cosette Pharmaceuticals Names Brad Leonard VP of Generics Commercial Operations

Cosette Pharmaceuticals a leading specialty pharmaceuticals company, has announced the appointment of Brad Leonard as Vice President, Generics Commercial Operations. This strategic move comes as the company continues its expansion in the generics market, reinforcing its commitment to leadership excellence…

Read MoreCosette Pharmaceuticals Names Brad Leonard VP of Generics Commercial Operations
Antibody

Antibody Breakthrough Inhalon Biopharma Unveils First Inhaled for RSV in Human Trials

Inhalon Biopharma a clinical-stage biotechnology company focused on developing innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the advancement of its inhaled antibody platform. The company has successfully completed Investigational New Drug (IND)-enabling studies for…

Read MoreAntibody Breakthrough Inhalon Biopharma Unveils First Inhaled for RSV in Human Trials

Enveric Biosciences Granted Patent Allowance for Lead Drug Candidate EB-003 by USPTO

Enveric Biosciences Secures Patent Protection for Breakthrough Neuroplastogen EB-003 In a significant milestone for its innovative drug development pipeline, Enveric Biosciences (NASDAQ: ENVB) has announced the receipt of a Notice of Allowance (NOA) from the United States Patent and Trademark…

Read MoreEnveric Biosciences Granted Patent Allowance for Lead Drug Candidate EB-003 by USPTO

RevBio Secures Key Patent for Regenerative Bone Adhesive Technology in the US

RevBio Secures 10th Patent for TETRANITE®: Expanding Protection for Revolutionary Bone Adhesive Technology In a significant milestone for regenerative medicine, ITS, a clinical-stage medical device company, has been granted its 10th U.S. patent for its groundbreaking TETRANITE® bone adhesive technology.…

Read MoreRevBio Secures Key Patent for Regenerative Bone Adhesive Technology in the US